Estrogen-receptor and PR markers have been demonstrated to be important prognostic factors for endocrine therapy [5, 6], whereas, the HER2 gene facilitates the onset, growth, and metastasis of breast cancer [7]. Here, ERBB2 is linked to breast carcinoma.